U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070466) titled 'Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA' on June 14.
Brief Summary: This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
Study Start Date: Dec. 12, 2025
Study Type: INTERVENTIONAL
Condition:
Stomach Cancer Stage IV
Esophagus Cancer
Stomach Cancer
Intervention:
DRUG: Ivonescimab
Humanized immunoglobulin G1 monoclonal antibody
DRUG: 5-Fluorouracil
Nucleoside metabolic inhibitor
DRUG: Oxaliplatin
Platinum-based drug and organoplatinum complex
DRUG: Leucovorin
5-formyl derivative of tetrahydrofolic acid...